8 Results

People

  1. Motzer
    Motzer
  2. Behr
    Behr
  3. Byun
    Byun
  4. Capanu
    Capanu
  5. Carlo
    Carlo
  6. Girotra
    Girotra
  7. Hellmann
    Hellmann
  8. Palomba
    Palomba
  9. Price
    Price
  10. Roeker
    Roeker

Groups

  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (4)
  3. Center for Hematologic Malignancies (2)
  4. Genitourinary Oncology Service (2)
  5. Hematologic Malignancies, Division of (2)
  6. Biostatistics Service (1)
  7. Body Imaging Service (1)
  8. Center for Pancreatic Cancer Research (1)
  9. Division of Subspecialty Medicine (1)
  10. Endocrinology (1)
  1. "long-term safety"
Formats
  1. Journal Article (7)
  2. Guidelines (1)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (4)
  3. Center for Hematologic Malignancies (2)
  4. Genitourinary Oncology Service (2)
  5. Hematologic Malignancies, Division of (2)
  6. Biostatistics Service (1)

More Groups

People
  1. Robert Motzer (2)
  2. Anita Price (1)
  3. Bianca Santomasso (1)
  4. David Byun (1)
  5. Gerald Behr (1)
  6. Jedd Wolchok (1)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2021 (2)
  4. 2018 (1)
  5. 2017 (1)
  6. 2016 (2)
Publications
  1. Journal of Clinical Oncology (2)
  2. Acta Haematologica (1)
  3. Clinical Imaging (1)
  4. European Urology (1)
  5. Nature Reviews Endocrinology (1)
  6. Nature Reviews Urology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. Nature Publishing Group (2)
  3. Elsevier Inc. (1)
  4. Elsevier Science, Inc. (1)
  5. S. Karger AG (1)
  6. Wiley Blackwell (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies
    Journal Article

    Roeker, L. E.; Coombs, C. C.; Shah, N. N.; Jurczak, W.; Woyach, J. A.; Cheah, C. Y.; Patel, K.; Maddocks, K.; Wang, Y.; Zinzani, P. L.; more...
    Acta Haematologica (2025)

    Fulltext@MSK | Save
  • Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
    Journal Article

    Lamanna, N.; Tam, C. S.; Woyach, J. A.; Alencar, A. J.; Palomba, M. L.; Zinzani, P. L.; Flinn, I. W.; Fakhri, B.; Cohen, J. B.; Kontos, A.; more...
    eJHaem (2024)

    Fulltext@MSK | Save
  • Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
    Guidelines

    Schneider, B. J.; Naidoo, J.; Santomasso, B. D.; Lacchetti, C.; Adkins, S.; Anadkat, M.; Atkins, M. B.; Brassil, K. J.; Caterino, J. M.; Chau, I.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Is IV contrast necessary for MRI follow-up in children with abdominal neuroblastoma?
    Journal Article

    Behr, G. G.; Zheng, J.; Capanu, M.; Price, A. P.
    Clinical Imaging (2021)

    Fulltext@MSK | Save
  • Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study
    Journal Article

    Gettinger, S.; Horn, L.; Jackman, D.; Spigel, D.; Antonia, S.; Hellmann, M.; Powderly, J.; Heist, R.; Sequist, L. V.; Smith, D. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cancer immunotherapy - Immune checkpoint blockade and associated endocrinopathies
    Journal Article

    Byun, D. J.; Wolchok, J. D.; Rosenberg, L. M.; Girotra, M.
    Nature Reviews Endocrinology (2017)

    Fulltext@MSK | Save
  • Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
    Journal Article

    Carlo, M. I.; Voss, M. H.; Motzer, R. J.
    Nature Reviews Urology (2016)

    Fulltext@MSK | Save
  • Long-term safety of sunitinib in metastatic renal cell carcinoma
    Journal Article

    Porta, C.; Gore, M. E.; Rini, B. I.; Escudier, B.; Hariharan, S.; Charles, L. P.; Yang, L.; Deannuntis, L.; Motzer, R. J.
    European Urology (2016)

    Fulltext@MSK | Save